The high rate of psoriasis patients with NRRs, especially among women, less educated and elderly patients, indicates a content validity problem of the measure. A reconsideration of the use of the DLQI for medical and financial decision-making in psoriasis patients is suggested.

11 Background There is a growing interest in policy making 12 for using utility measures and identifying algorithms to 13 convert disease-specific measures into utilities. 14 Objectives To analyse the relationship between EQ-5D, 15 Dermatology Life Quality Index (DLQI) and Psoriasis 16 Area and Severity Index (PASI) in psoriasis. To transform 17 DLQI scores, and key clinical, demographic and health 18 service utilisation variables into utilities. 19 Methods A cross-sectional questionnaire survey of 200 20 consecutive adult patients with moderate to severe psoria-21 sis was carried out in two Hungarian university clinics. The 22 relationship between the outcome measures were analysed 23 with correlations and with the known-groups method. 24 Bivariate and multivariate regression algorithms on EQ-5D 25 scores were formulated. 26Results The mean age of respondents was 51 years 27 (SD = 12.9), 68.5 % were male, and 51.5 % received 28 biological therapy. Median EQ-5D, DLQI, and PASI scores 29 were 0.73, 3.0, and 3.45, respectively. EQ-5D showed a 30 moderate correlation with the DLQI and with the PASI 31 (r s = -0.48 and -0.43, p \ 0.05). Strong correlation was 32 found between DLQI and PASI (r s = 0.81, p \ 0.05). 33 DLQI and PASI discriminated better among groups cate-34 gorised by the localisation of the lesions than EQ-5D.

This study reveals a dominant TH17 response of cutaneous lymphocyte antigen-positive T cells activated by epidermal cells and S pyogenes in patients with GP.

10 Background Despite the widespread availability of bio-11 logical drugs in psoriasis, there is a shortage of disease 12 burden studies. 13 Objectives To assess the cost-of-illness and quality of 14 life of patients with moderate to severe psoriasis in 15 Hungary. 16 Methods Consecutive patients with Psoriasis Area and 17 Severity Index (PASI) [ 10 and Dermatology Life Quality 18 Index (DLQI) [ 10, or treated with traditional systemic 19 (TST) or biological systemic treatment (BST) were inclu-20 ded. Demographic data, clinical characteristics, psoriasis 21 related medication, health care utilizations and employ-22 ment status in the previous 12 months were recorded. 23 Costing was performed from the societal perspective 24 applying the human capital approach. Quality of life was 25 assessed using DLQI and EQ-5D measures. 26 Results Two-hundred patients were involved (females 27 32 %) with a mean age of 51 (SD 13) years, 103 (52 %) 28 patients were on BST. Mean PASI, DLQI and EQ-5D 29 scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), 30 respectively. The mean total cost was €9,254/patient/year 31 (SD 8,502) with direct costs accounting for 86 %. The 32 main cost driver was BST (mean €7,339/patient/year).

Our findings highlight the importance of exploring expectations that might help to increase patients' compliance.